LifePoint Health (NASDAQ:LPNT) updated its FY18 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of $4.00-4.53 for the period, compared to the Thomson Reuters consensus estimate of $4.09. The company issued revenue guidance of $6.35-6.43 billion, compared to the consensus revenue estimate of $6.49 billion.
A number of brokerages have recently issued reports on LPNT. Cantor Fitzgerald reiterated a hold rating and set a $50.00 price target on shares of LifePoint Health in a research report on Friday. Robert W. Baird set a $55.00 price target on LifePoint Health and gave the company a buy rating in a research report on Monday, October 30th. BidaskClub upgraded LifePoint Health from a sell rating to a hold rating in a research report on Thursday, January 11th. ValuEngine downgraded LifePoint Health from a buy rating to a hold rating in a research report on Friday, February 2nd. Finally, Zacks Investment Research upgraded LifePoint Health from a strong sell rating to a hold rating in a research report on Monday, January 22nd. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and five have issued a buy rating to the company. The stock has an average rating of Hold and an average target price of $58.13.
LifePoint Health (LPNT) traded up $0.60 during trading hours on Friday, reaching $49.70. The company had a trading volume of 601,000 shares, compared to its average volume of 539,309. The company has a market cap of $1,935.31, a P/E ratio of 11.75, a price-to-earnings-growth ratio of 1.12 and a beta of 0.52. LifePoint Health has a one year low of $41.45 and a one year high of $67.95. The company has a quick ratio of 1.65, a current ratio of 1.85 and a debt-to-equity ratio of 1.24.
LifePoint Health announced that its board has authorized a share buyback program on Friday, October 27th that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the company to buy shares of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.
In related news, insider David M. Dill sold 45,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $48.52, for a total value of $2,183,400.00. Following the completion of the sale, the insider now owns 252,673 shares in the company, valued at approximately $12,259,693.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Marguerite Kondracke sold 3,907 shares of the business’s stock in a transaction that occurred on Tuesday, November 28th. The stock was sold at an average price of $44.73, for a total value of $174,760.11. The disclosure for this sale can be found here. Insiders own 8.76% of the company’s stock.
About LifePoint Health
LifePoint Health, Inc, through its subsidiaries, owns and operates community hospitals, regional health systems, physician practices, outpatient centers and post-acute facilities. As of December 31, 2016, the Company operated 72 hospital campuses in 22 states, having a total of 9,424 licensed beds. It offers a range of general and specialized healthcare services to patients through a network of hospitals and outpatient facilities.
Receive News & Ratings for LifePoint Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifePoint Health and related companies with MarketBeat.com's FREE daily email newsletter.